Decoy Therapeutics is trading 6.7% down at $4.08 as the stock gives back a portion of its sharp rebound from late-July lows.
- There are no fresh company-specific headlines, earnings releases, or analyst actions on August 5, 2026, to directly explain the move.
- The broader biotech sector is currently trading higher, suggesting the decline is driven by stock-specific volatility and profit-taking rather than a reaction to new information.